UPDATE 1-Cumberland says injection meets main goal in study

* Says Caldolor can be administered for 5 consecutive days

* Says study raised no safety concerns

Nov 23 (Reuters) - Cumberland Pharmaceuticals Inc (CPIX.O) said its pain and fever treatment Caldolor met the main goal of reducing fever in burn patients over the first 24 hours of treatment in a study.

The drug was well tolerated and can be administered to the hospitalized patients for five consecutive days without any safety issues, the company said.

Patients were administered 800 milligrams of Caldolor every six hours for five consecutive days.

In June, Nashville-based Cumberland had received U.S. regulatory approval for Caldolor, which is administered intravenously, and had launched the product in September.

Shares of the company were trading down 31 cents at $15.13 Monday morning on Nasdaq. (Reporting by Anuradha Ramanathan in Bangalore; Editing by Aradhana Aravindan) ((anuradha.ramanathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800: Reuters Messaging: anuradha.ramanathan.reuters.com@reuters.net))